BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26603598)

  • 1. Natural history and treatment trends in hepatocellular carcinoma subtypes: Insights from a national cancer registry.
    Jernigan PL; Wima K; Hanseman DJ; Hoehn RS; Ahmad SA; Shah SA; Abbott DE
    J Surg Oncol; 2015 Dec; 112(8):872-6. PubMed ID: 26603598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection.
    Malouf GG; Brugières L; Le Deley MC; Faivre S; Fabre M; Paradis V; Aerts I; Le Tourneau C; Dreyer C; Branchereau S; Belghiti J; Raymond E
    Cancer; 2012 Oct; 118(20):4981-90. PubMed ID: 22415897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
    J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of patients with fibrolamellar hepatocellular carcinoma.
    Stipa F; Yoon SS; Liau KH; Fong Y; Jarnagin WR; D'Angelica M; Abou-Alfa G; Blumgart LH; DeMatteo RP
    Cancer; 2006 Mar; 106(6):1331-8. PubMed ID: 16475212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing trends in long-term outcomes after hepatic resection for hepatocellular carcinoma: A 30-year, single-center experience.
    Yamamoto Y; Ikoma H; Morimura R; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
    Anticancer Res; 2013 Nov; 33(11):5097-105. PubMed ID: 24222155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience.
    Weeda VB; Murawski M; McCabe AJ; Maibach R; Brugières L; Roebuck D; Fabre M; Zimmermann A; Otte JB; Sullivan M; Perilongo G; Childs M; Brock P; Zsíros J; Plaschkes J; Czauderna P; Aronson DC
    Eur J Cancer; 2013 Aug; 49(12):2698-704. PubMed ID: 23683550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area.
    Lee JH; Kim HY; Kim YJ; Yoon JH; Chung JW; Lee HS
    J Gastroenterol Hepatol; 2015 Apr; 30(4):696-705. PubMed ID: 25250761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrolamellar hepatocellular carcinoma in children and adolescents.
    Katzenstein HM; Krailo MD; Malogolowkin MH; Ortega JA; Qu W; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Newman K; Finegold MJ; Haas JE; Sensel MG; Castleberry RP; Bowman LC
    Cancer; 2003 Apr; 97(8):2006-12. PubMed ID: 12673731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma downstaging in liver transplantation.
    Yu CY; Ou HY; Huang TL; Chen TY; Tsang LL; Chen CL; Cheng YF
    Transplant Proc; 2012 Mar; 44(2):412-4. PubMed ID: 22410030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of survival after resection of early hepatocellular carcinoma.
    Nathan H; Schulick RD; Choti MA; Pawlik TM
    Ann Surg; 2009 May; 249(5):799-805. PubMed ID: 19387322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour epithelial and stromal characteristics of hepatocellular carcinomas with abundant fibrous stroma: fibrolamellar versus scirrhous hepatocellular carcinoma.
    Kim YJ; Rhee H; Yoo JE; Alves VAF; Kim GJ; Kim HM; Herman P; Chagas A; Kim H; Park YN
    Histopathology; 2017 Aug; 71(2):217-226. PubMed ID: 28326574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
    World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments.
    Kassahun WT
    World J Surg Oncol; 2016 May; 14(1):151. PubMed ID: 27215576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival.
    Stuart KE; Anand AJ; Jenkins RL
    Cancer; 1996 Jun; 77(11):2217-22. PubMed ID: 8635087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.
    Bräu N; Fox RK; Xiao P; Marks K; Naqvi Z; Taylor LE; Trikha A; Sherman M; Sulkowski MS; Dieterich DT; Rigsby MO; Wright TL; Hernandez MD; Jain MK; Khatri GK; Sterling RK; Bonacini M; Martyn CA; Aytaman A; Llovet JM; Brown ST; Bini EJ;
    J Hepatol; 2007 Oct; 47(4):527-37. PubMed ID: 17692986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.
    Pan K; Li YQ; Wang W; Xu L; Zhang YJ; Zheng HX; Zhao JJ; Qiu HJ; Weng DS; Li JJ; Wang QJ; Huang LX; He J; Chen SP; Ke ML; Wu PH; Chen MS; Li SP; Xia JC; Zeng YX
    Ann Surg Oncol; 2013 Dec; 20(13):4305-11. PubMed ID: 23892527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
    Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
    Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience.
    Lemekhova A; Hornuss D; Polychronidis G; Mayer P; Rupp C; Longerich T; Weiss KH; Büchler M; Mehrabi A; Hoffmann K
    World J Surg Oncol; 2020 May; 18(1):93. PubMed ID: 32397993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
    Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
    Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation.
    Kim PT; Onaca N; Chinnakotla S; Davis GL; Jennings LW; McKenna GJ; Ruiz RM; Levy MF; Goldstein R; Klintmalm GB
    Clin Transplant; 2013; 27(2):311-8. PubMed ID: 23351129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.